Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells.

ABSTRACT: Targeted pharmacologic activation of antigen-specific (AgS) T cells may bypass limitations inherent in current T cell-based cancer therapies. We describe two immunotherapeutics platforms for selective delivery of costimulatory ligands and peptide-HLA (pHLA) to AgS T cells. We engineered and deployed on these platforms an affinity-attenuated variant of interleukin-2, which selectively expands oligoclonal and polyfunctional AgS T cells in vitro and synergizes with CD80 signals for superior proliferation versus peptide stimulation.

SUBMITTER: Seidel RD 

PROVIDER: S-EPMC8479091 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature